Back to top

oncology-screening: Archive

Zacks Equity Research

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

JNJNegative Net Change MRKNegative Net Change IBRXNegative Net Change CGONPositive Net Change

Zacks Equity Research

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.

BAYRYNegative Net Change EXELPositive Net Change EDITNegative Net Change ALLONegative Net Change